How have the shares performed?
Prelude Therapeutics Incorporated (PRLD) saw an uptrend of 8.27% in the recent trading with $33.78 being its most recent. The current price level -64.58% lower than the highest price of $95.38 marked by the stock while trading over the past 52-weeks, whereas it is 42.57% higher than the lowest price of $23.69 the company dropped to over past 52-weeks. The latest news story on PRLD appeared in Simply Wall St. under the title “Are Insiders Buying Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock?” on May-13-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -22.86% below one month high and is +14.24% above of the lowest during that time. Looking into the simple moving average, Prelude Therapeutics Incorporated (PRLD)’s stock stands at a SMA-50 of $36.38 while that of 5-day is reading $31.81.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
Prelude Therapeutics Incorporated Earnings – What Happened With PRLD
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Prelude Therapeutics Incorporated (PRLD) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of -11.90% for net revenue.
PRLD – Prelude Therapeutics Incorporated Stock Earnings Estimates
The perspective of Prelude Therapeutics Incorporated (NASDAQ:PRLD)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.42 for stock’s EPS in the current quarter. 5 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.47.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 45.12 million. PRLD does have institutional investors; and they hold 81.50% of the stock.
Prelude Therapeutics Incorporated – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 16 new insider purchases involving 151,979 shares. On the other hand, PRLD declared 151,979 shares have been sold in 37 insider transactions over the past three months.
As on Mar 30, 2021, Orbimed Advisors LLC. was the top most holder in Prelude Therapeutics Incorporated (NASDAQ:PRLD) with an ownership of 15.72 million shares of the company or 33.48% of the stake worth $681.14 million. The filing also reveals Baker Brothers Advisors, LLC as the second largest holder in the company with a control over 21.56% of the outstanding shares. Its stake is worth $438.67 million for having 10.12 million shares in hand.
FMR, LLC also came holding a key position in the company during the recent quarter and it now holds 13.31% of the outstanding shares. With this there are now 90 institutions which have possession in PRLD’s shares.
Currently, the stock has been recommended as Moderate Buy by 5 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Prelude Therapeutics Incorporated was 19.41 while posting a debt to equity ratio of 0.00.